Antibody responses to respiratory syncytial virus: a population-based cross-sectional serological study in Southern China, 2021
- PMID: 38852851
- PMCID: PMC11342021
- DOI: 10.1016/j.cmi.2024.06.005
Antibody responses to respiratory syncytial virus: a population-based cross-sectional serological study in Southern China, 2021
Abstract
Objectives: With remarkable progress in the field of respiratory syncytial virus (RSV) prophylaxis, it is critical to understand population immunity against RSV. We aim to describe the RSV pre-F IgG antibodies across all age groups in Southern China and to evaluate the risk factors associated with lower antibody levels.
Methods: We performed a community-based cross-sectional sero-epidemiological study in Anhua County, Hunan Province, Southern China, from July 15, 2021, to November 5, 2021. Serum samples were tested for IgG antibodies against the RSV prefusion F (pre-F) protein using an enzyme-linked immunosorbent assay. We estimated the geometric mean titres (GMTs) and seropositivity rates across all age groups. The generalized linear models were built to identify factors associated with antibody levels.
Results: A total of 890 participants aged 4 months to older than 89 years were enrolled. The lowest RSV pre-F IgG GMTs were observed in infants and toddlers aged 4 months to younger than 2 years (3.0; 95% CI, 2.6-3.5). With increasing age, the RSV pre-F IgG GMT increased to 4.3 (95% CI, 4.1-4.4) between the ages of 2 and younger than 5 years and then stabilized at high levels throughout life. All the children had serological evidence of RSV infection by the age of 5 years. Age was associated with RSV pre-F antibody levels in children, with an estimated 1.9-fold (95% CI, 0.8-3.6) increase in titre per year before 5 years of age, although it was not significantly associated with antibody levels in adults aged older than 60 years.
Discussion: Our findings could provide a comprehensive understanding of the gaps in RSV immunity at the population level and inform the prioritization of immunization platforms.
Keywords: Cross-sectional study; General population; Pre-F IgG antibody; Respiratory syncytial virus; Serology.
Copyright © 2024 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
Conflict of interest statement
Transparency declaration
H.Y. has received research funding from Sanofi Pasteur, GlaxoSmithKline, Yichang HEC Changjiang and Shanghai Roche Pharmaceutical Company. None of the research funding is related to this work.
H.Y.C. reports consulting with Ellume, Pfizer, and the Bill and Melinda Gates Foundation. She has served on advisory boards for Vir, Merck and Abbvie. She has conducted CME teaching with Medscape, Vindico, and Clinical Care Options. She has received research funding from Gates Ventures, and support and reagents from Ellume and Cepheid, all outside of the submitted work.
All other authors report no competing interests.
Similar articles
-
Strength and Durability of Respiratory Syncytial Virus Prefusion F Immunoglobulin G Following Infection and Exposure in a Household Cohort, 2014-2022.J Infect Dis. 2025 Jul 11;231(6):e1138-e1145. doi: 10.1093/infdis/jiaf168. J Infect Dis. 2025. PMID: 40176487 Free PMC article.
-
Antibody Responses to Respiratory Syncytial Virus: A Cross-Sectional Serosurveillance Study in the Dutch Population Focusing on Infants Younger Than 2 Years.J Infect Dis. 2021 Jul 15;224(2):269-278. doi: 10.1093/infdis/jiaa483. J Infect Dis. 2021. PMID: 32964923 Free PMC article.
-
Age-Specific Profiles of Antibody Responses against Respiratory Syncytial Virus Infection.EBioMedicine. 2017 Feb;16:124-135. doi: 10.1016/j.ebiom.2017.01.014. Epub 2017 Jan 16. EBioMedicine. 2017. PMID: 28111238 Free PMC article.
-
The third pandemic: The respiratory syncytial virus landscape and specific considerations for the allergist/immunologist.Allergy Asthma Proc. 2023 Jul 26;44(4):220-228. doi: 10.2500/aap.2023.44.230030. Allergy Asthma Proc. 2023. PMID: 37236777 Review.
-
Passive protection against respiratory syncytial virus disease in infants: the role of maternal antibody.Pediatr Infect Dis J. 1994 May;13(5):449-53. doi: 10.1097/00006454-199405000-00037. Pediatr Infect Dis J. 1994. PMID: 8072835 Review.
Cited by
-
Strength and Durability of Respiratory Syncytial Virus Prefusion F Immunoglobulin G Following Infection and Exposure in a Household Cohort, 2014-2022.J Infect Dis. 2025 Jul 11;231(6):e1138-e1145. doi: 10.1093/infdis/jiaf168. J Infect Dis. 2025. PMID: 40176487 Free PMC article.
-
Global outbreaks of respiratory syncytial virus infections from 1960 to 2025: a systematic review and meta-analysis.EClinicalMedicine. 2025 Jul 10;86:103352. doi: 10.1016/j.eclinm.2025.103352. eCollection 2025 Aug. EClinicalMedicine. 2025. PMID: 40666171 Free PMC article.
References
-
- Li Y, Wang X, Blau DM, Caballero MT, Feikin DR, Gill CJ, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet. 2022;399(10340):2047–64. 10.1016/S0140-6736(22)00478-0 - DOI - PMC - PubMed
-
- Shi T, Denouel A, Tietjen AK, Campbell I, Moran E, Li X, et al. Global Disease Burden Estimates of Respiratory Syncytial Virus-Associated Acute Respiratory Infection in Older Adults in 2015: A Systematic Review and Meta-Analysis. J Infect Dis. 2020;222(Suppl 7):S577–s83. 10.1093/infdis/jiz059 - DOI - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical